Clopidogrel Krka d.d. (previously Zopya)

clopidogrel

  • Email
  • Help

About

This is a summary of the European public assessment report (EPAR) for Clopidogrel Krka d.d. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Clopidogrel Krka d.d.

What is Clopidogrel Krka d.d.?

Clopidogrel Krka d.d. is a medicine that contains the active substance clopidogrel. It is available as pink, round tablets (75 mg).

Clopidogrel Krka d.d. is a ‘generic medicine’. This means that Clopidogrel Krka d.d. is similar to a ‘reference medicine’ already authorised in the European Union (EU) called Plavix.

What is Clopidogrel Krka d.d. used for?

Clopidogrel Krka d.d. is used in adults to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries). Clopidogrel Krka d.d. can be given to the following groups of patients:

  • patients who have recently had a myocardial infarction (heart attack). Clopidogrel Krka d.d. can be started between a few days and 35 days after the attack;
  • patients who have had a recent ischaemic stroke (stroke caused by failure of the blood supply to part of the brain). Clopidogrel Krka d.d. can be started between seven days and six months after the stroke;
  • patients with peripheral arterial disease (problems with blood flow in the arteries).

The medicine can only be obtained with a prescription.

How is Clopidogrel Krka d.d. used?

The standard dose of Clopidogrel Krka d.d. is one 75 mg tablet once a day, taken with or without food.

How does Clopidogrel Krka d.d. work?

The active substance in Clopidogrel Krka d.d., clopidogrel, is an inhibitor of platelet aggregation. This means that it helps to prevent blood clots from forming. When the blood clots, this is due to special cells in the blood called platelets aggregating (sticking together). Clopidogrel stops the platelets aggregating by blocking a substance called ADP from attaching to a special receptor on their surface. This stops the platelets becoming ‘sticky’, reducing the risk of a blood clot forming and helping to prevent another heart attack or stroke.

How has Clopidogrel Krka d.d. been studied?

Because Clopidogrel Krka d.d. is a generic medicine, studies have been limited to tests to determine that it is bioequivalent to the reference medicine, Plavix. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

What are the benefits and risks of Clopidogrel Krka d.d.?

Because Clopidogrel Krka d.d. is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.

Why has Clopidogrel Krka d.d. been approved?

The CHMP concluded that, in accordance with EU requirements, Clopidogrel Krka d.d. has been shown to have comparable quality and to be bioequivalent to Plavix. Therefore, the CHMP’s view was that, as for Plavix, the benefit outweighs the identified risk. The Committee recommended that Clopidogrel Krka d.d. be given marketing authorisation.

Other information about Clopidogrel Krka d.d.

The European Commission granted a marketing authorisation valid throughout the EU for Zopya on 21 September 2009. The name of the medicine was changed to Clopidogrel Krka d.d. on 18 May 2011.

For more information about treatment with Clopidogrel Krka d.d., read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Name Language First published Last updated
Clopidogrel Krka d.d. : EPAR - Summary for the public BG = bălgarski 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - Summary for the public ES = español 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - Summary for the public CS = čeština 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - Summary for the public DA = dansk 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - Summary for the public DE = Deutsch 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - Summary for the public ET = eesti keel 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - Summary for the public EL = elliniká 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - Summary for the public EN = English 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - Summary for the public FR = français 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - Summary for the public IT = italiano 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - Summary for the public LV = latviešu valoda 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - Summary for the public LT = lietuvių kalba 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - Summary for the public HU = magyar 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - Summary for the public MT = Malti 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - Summary for the public NL = Nederlands 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - Summary for the public PL = polski 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - Summary for the public PT = português 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - Summary for the public RO = română 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - Summary for the public SK = slovenčina 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - Summary for the public SL = slovenščina 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - Summary for the public FI = suomi 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - Summary for the public SV = svenska 14/10/2009 23/01/2012

This EPAR was last updated on 11/01/2016 .

Authorisation details

Product details

Product details for Clopidogrel Krka d.d. (previously Zopya)
NameClopidogrel Krka d.d. (previously Zopya)
Agency product numberEMEA/H/C/001137
Active substance

clopidogrel hydrochloride

International non-proprietary name (INN) or common name

clopidogrel

Therapeutic area Peripheral Vascular DiseasesStrokeMyocardial Infarction
Anatomical therapeutic chemical (ATC) code B01AC03
Generic

A generic medicine is a medicine which is similar to a medicine that has already been authorised (the 'reference medicine'). A generic medicine contains the same quantity of active substance(s) as the reference medicine. Generic and reference medicines are used at the same dose to treat the same disease, and they are equally safe and effective.

Publication details

Publication details for Clopidogrel Krka d.d. (previously Zopya)
Marketing-authorisation holder

Krka, d.d., Novo mesto

Revision6
Date of issue of marketing authorisation valid throughout the European Union21/09/2009

Contact address:

Krka, d.d., Novo mesto
Šmarješka cesta 6
8501 Novo mesto
Slovenia

Product information

Product information

08/12/2015  Clopidogrel Krka d.d. (previously Zopya) -EMEA/H/C/001137 -IB/0023/G

Name Language First published Last updated
Clopidogrel Krka d.d. : EPAR - Product Information SV = svenska 14/10/2009 11/01/2016
Clopidogrel Krka d.d. : EPAR - Product Information SV = svenska 14/10/2009 11/01/2016
Clopidogrel Krka d.d. : EPAR - Product Information SV = svenska 14/10/2009 11/01/2016
Clopidogrel Krka d.d. : EPAR - Product Information SV = svenska 14/10/2009 11/01/2016
Clopidogrel Krka d.d. : EPAR - Product Information SV = svenska 14/10/2009 11/01/2016
Clopidogrel Krka d.d. : EPAR - Product Information SV = svenska 14/10/2009 11/01/2016
Clopidogrel Krka d.d. : EPAR - Product Information SV = svenska 14/10/2009 11/01/2016
Clopidogrel Krka d.d. : EPAR - Product Information SV = svenska 14/10/2009 11/01/2016
Clopidogrel Krka d.d. : EPAR - Product Information SV = svenska 14/10/2009 11/01/2016
Clopidogrel Krka d.d. : EPAR - Product Information SV = svenska 14/10/2009 11/01/2016
Clopidogrel Krka d.d. : EPAR - Product Information SV = svenska 14/10/2009 11/01/2016
Clopidogrel Krka d.d. : EPAR - Product Information SV = svenska 14/10/2009 11/01/2016
Clopidogrel Krka d.d. : EPAR - Product Information SV = svenska 14/10/2009 11/01/2016
Clopidogrel Krka d.d. : EPAR - Product Information SV = svenska 14/10/2009 11/01/2016
Clopidogrel Krka d.d. : EPAR - Product Information SV = svenska 14/10/2009 11/01/2016
Clopidogrel Krka d.d. : EPAR - Product Information SV = svenska 14/10/2009 11/01/2016
Clopidogrel Krka d.d. : EPAR - Product Information SV = svenska 14/10/2009 11/01/2016
Clopidogrel Krka d.d. : EPAR - Product Information SV = svenska 14/10/2009 11/01/2016
Clopidogrel Krka d.d. : EPAR - Product Information SV = svenska 14/10/2009 11/01/2016
Clopidogrel Krka d.d. : EPAR - Product Information SV = svenska 14/10/2009 11/01/2016
Clopidogrel Krka d.d. : EPAR - Product Information SV = svenska 14/10/2009 11/01/2016
Clopidogrel Krka d.d. : EPAR - Product Information SV = svenska 14/10/2009 11/01/2016
Clopidogrel Krka d.d. : EPAR - Product Information SV = svenska 14/10/2009 11/01/2016
Clopidogrel Krka d.d. : EPAR - Product Information SV = svenska 14/10/2009 11/01/2016
Clopidogrel Krka d.d. : EPAR - Product Information SV = svenska 14/10/2009 11/01/2016

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.


Name Language First published Last updated
Clopidogrel Krka d.d. : EPAR - All Authorised presentations SV = svenska 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - All Authorised presentations SV = svenska 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - All Authorised presentations SV = svenska 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - All Authorised presentations SV = svenska 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - All Authorised presentations SV = svenska 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - All Authorised presentations SV = svenska 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - All Authorised presentations SV = svenska 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - All Authorised presentations SV = svenska 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - All Authorised presentations SV = svenska 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - All Authorised presentations SV = svenska 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - All Authorised presentations SV = svenska 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - All Authorised presentations SV = svenska 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - All Authorised presentations SV = svenska 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - All Authorised presentations SV = svenska 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - All Authorised presentations SV = svenska 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - All Authorised presentations SV = svenska 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - All Authorised presentations SV = svenska 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - All Authorised presentations SV = svenska 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - All Authorised presentations SV = svenska 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - All Authorised presentations SV = svenska 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - All Authorised presentations SV = svenska 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - All Authorised presentations SV = svenska 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - All Authorised presentations SV = svenska 14/10/2009 23/01/2012
Clopidogrel Krka d.d. : EPAR - All Authorised presentations SV = svenska 14/10/2009 23/01/2012

Pharmacotherapeutic group

Antithrombotic agents

Therapeutic indication

Prevention of atherothrombotic events

Clopidogrel is indicated in:

  • Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
  • Adult patients suffering from acute coronary syndrome:
  • Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).
  • ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.

Prevention of atherothrombotic and thromboembolic events in atrial fibrillation

In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with Vitamin K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.

Assessment History

Changes since initial authorisation of medicine

Name Language First published Last updated
Clopidogrel Krka d.d.: EPAR - Procedural steps taken and scientific information after authorisation SV = svenska 25/03/2010 11/01/2016

Initial marketing-authorisation documents

Name Language First published Last updated
Zopya : EPAR - Public assessment report SV = svenska 14/10/2009  
Committee for medicinal products for human use summary of positive opinion for Zopya SV = svenska 24/06/2009  

Authorised

This medicine is approved for use in the European Union

More information on Clopidogrel Krka d.d.